Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
Eton Pharmaceuticals, Inc. amended a asset purchase with Azurity Pharmaceuticals, Inc. valued at $5.5 million (effective 2023-06-15).
- Action
- amendment
- Agreement
- asset purchase
- Counterparty
- Azurity Pharmaceuticals, Inc.
- Value
- $5.5 million
- Effective
- 2023-06-15
Exact text from the filing
Also, on June 15, 2023, the Company entered into an amendment to the Asset Purchase Agreement dated December 31, 2020 (the “Original Agreement”) by and between the Company and Azurity Pharmaceuticals, Inc. (“Azurity”). Under the amendment, the Company will sell back to Azurity the royalty interests it received under the Original Agreement for a total consideration of $5.5 million.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
Eton Pharmaceuticals, Inc. entered into Asset Purchase Agreement with Wellstat Therapeutics Corporation, Wellstat Biologics Corporation, Janet M. Nesse, as Bankruptcy Trustee, and certain other affiliates valued at $37 million (effective 2023-06-09).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Wellstat Therapeutics Corporation, Wellstat Biologics Corporation, Janet M. Nesse, as Bankruptcy Trustee, and certain other affiliates
- Value
- $37 million
- Effective
- 2023-06-09
Exact text from the filing
On June 9, 2023, Eton Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation (collectively, the “Debtors”), Janet M. Nesse, as Bankruptcy Trustee for the bankruptcy estates of the Debtors, and certain other affiliates of the Debtors, whereby the Company was named the “stalking horse bidder” in the bankruptcy proceedings of the Debtors and agreed to acquire the commercial assets of the Debtors for consideration of $37 million.
View on SEC.gov